KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Payables: 2009-2025

Historic Payables for Neogenomics (NEO) over the last 16 years, with Sep 2025 value amounting to $22.6 million.

  • Neogenomics' Payables fell 89.58% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $489.8 million, marking a year-over-year increase of 3.59%. This contributed to the annual value of $222.4 million for FY2024, which is 993.66% up from last year.
  • Neogenomics' Payables amounted to $22.6 million in Q3 2025, which was down 17.75% from $27.5 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Payables registered a high of $222.4 million during Q4 2024, and its lowest value of $13.7 million during Q3 2022.
  • Its 3-year average for Payables is $92.7 million, with a median of $22.7 million in 2023.
  • In the last 5 years, Neogenomics' Payables spiked by 1,189.84% in 2024 and then tumbled by 89.58% in 2025.
  • Neogenomics' Payables (Quarterly) stood at $17.9 million in 2021, then increased by 14.45% to $20.5 million in 2022, then fell by 0.86% to $20.3 million in 2023, then spiked by 993.66% to $222.4 million in 2024, then tumbled by 89.58% to $22.6 million in 2025.
  • Its Payables was $22.6 million in Q3 2025, compared to $27.5 million in Q2 2025 and $217.3 million in Q1 2025.